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ARTICLE
Allosteric regulation of lysosomal enzyme
recognition by the cation-independent mannose
6-phosphate receptor
Linda J. Olson 1✉, Sandeep K. Misra 2, Mayumi Ishihara3, Kevin P. Battaile 4,6, Oliver C. Grant 3,
Amika Sood3, Robert J. Woods3, Jung-Ja P. Kim 1, Michael Tiemeyer3, Gang Ren 5, Joshua S. Sharp2 &
Nancy M. Dahms1✉
The cation-independent mannose 6-phosphate receptor (CI-MPR, IGF2 receptor or CD222),
is a multifunctional glycoprotein required for normal development. Through the receptor’s
ability to bind unrelated extracellular and intracellular ligands, it participates in numerous
functions including protein trafficking, lysosomal biogenesis, and regulation of cell growth.
Clinically, endogenous CI-MPR delivers infused recombinant enzymes to lysosomes in the
treatment of lysosomal storage diseases. Although four of the 15 domains comprising CI-
MPR’s extracellular region bind phosphorylated glycans on lysosomal enzymes, knowledge of
how CI-MPR interacts with ~60 different lysosomal enzymes is limited. Here, we show by
electron microscopy and hydroxyl radical protein footprinting that the N-terminal region of
CI-MPR undergoes dynamic conformational changes as a consequence of ligand binding and
different pH conditions. These data, coupled with X-ray crystallography, surface plasmon
resonance and molecular modeling, allow us to propose a model explaining how high-affinity
carbohydrate binding is achieved through allosteric domain cooperativity.
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Lysosomes are acidified organelles that carry out degradativemetabolism critical to many endocytic, phagocytic, andautophagic processes1,2. This diverse degradative capacity
depends on a collection of over 60 different soluble proteases,
glycosidases, nucleases, and lipases. Delivery of these newly syn-
thesized hydrolytic enzymes to lysosomes depends on the P-type
lectins, 300-kDa cation-independent mannose 6-phosphate
receptor (CI-MPR) and 46-kDa cation-dependent MPR (CD-
MPR), that bind the carbohydrate determinant, mannose
6-phosphate (M6P), on lysosomal enzymes. CI-MPR, which is the
primary receptor responsible for this intracellular trafficking1,
binds multiple ligands3 at the cell surface that include M6P-
containing cytokines4 and non-M6P-containing molecules (e.g.,
insulin-like growth factor 2 (IGF2)5, plasminogen6, urokinase-
type plasminogen activator receptor (uPAR)) to mediate CI-
MPR’s roles as a tumor suppressor7 and regulator of cell growth
and differentiation8. Given these many functions, it is not sur-
prising that mice lacking the CI-MPR gene die at birth9,10.
Mutations in lysosomal proteins (mainly enzymes) that result
in defective catabolism and substrate accumulation cause lyso-
somal storage diseases (LSDs). A characteristic of this family of
~70 LSDs is their progressive and debilitating nature due to their
impact on multiple organ systems. Treatment is symptomatic for
most LSDs, with only 11 having FDA-approved therapies. For
example, deficiency of palmitoyl-protein thioesterase 1 (PPT1)
causes the fatal neurodegenerative disorder infantile neuronal
ceroid lipofuscinosis, and there are no FDA-approved treatments
for these infants11. CI-MPR’s ability to internalize recombinant
M6P-containing enzymes delivered to patients by bi-weekly
intravenous infusion forms the basis of enzyme replacement
therapy for nine of these FDA-approved therapies12,13. Despite
CI-MPR’s critical function in supplying lysosomes with hydro-
lases and its role in human therapies, knowledge of how CI-MPR
interacts with a heterogeneous population of ~60 different lyso-
somal enzymes is lacking. Furthermore, no structure of CI-MPR
or CD-MPR in complex with an enzyme is available.
Many lectins bind sugars by simultaneously engaging multiple
sugar-binding sites, termed carbohydrate recognition domains
(CRDs). These CRDs are located on (1) a single polypeptide chain
(tandem repeats of CRDs) or (2) different polypeptide chains
(hetero-oligomers or clustering of monomers on the cell surface).
The resulting multivalent interactions significantly increase ligand
affinity14. CI-MPR’s extracytoplasmic region contains 15 homo-
logous domains called “mannose 6-phosphate receptor homol-
ogy” domains (MRH) due to their similar size (~150 residues)
and conserved residues, including disulfide bonding15. CI-MPR
has four non-adjacent CRDs (domains 3, 5, 9, and 15), each with
distinctive phosphomonoester and phosphodiester glycan pre-
ferences16–18. Our crystal and NMR structures of MRH domains
1–3 and 5 of CI-MPR19,20, the structures solved by Jones et al. of
domains 11–1421, along with the recently published cryo-EM
structure of endogenous CI-MPR22 reveal that each MRH
domain has a similar β-barrel fold. Furthermore, although
domain–domain interactions have been shown to stabilize the
binding site for IGF2 (domain 11)23 and M6P (domain 3)19, how
these interactions influence the function and overall structural
dynamics of CI-MPR is not fully understood.
We now report the crystal structures of the N-terminal five
domains of human CI-MPR, revealing the orientation of two
CRDs (domains 3 and 5) with respect to each other at pH 5.5 and
7.0. Analyses of the receptor bound to PPT1 by small-angle X-ray
scattering (SAXS) and hydroxyl radical protein footprinting
(HRPF) and under different pH conditions (e.g., Golgi, late
endosome) support binding and pH-induced conformational
change. In addition, negative-staining electron microscopy (EM)
images indicate that CI-MPR adopts multiple conformations
influenced by M6P binding. Furthermore, quantitative binding
measurements, coupled with biophysical analyses, support allos-
teric regulation of the two CRDs.
Results
Effects of ligand binding on domain orientation. Of the 15
MRH domains, we focused on the N-terminal five domains of CI-
MPR containing two CRDs and the interaction site of plasmi-
nogen and uPAR (Fig. 1a). Crystallization screening of human
CI-MPR domains 1–5 protein in the presence of 10-mM M6P
resulted in two conditions yielding diffraction quality crystals.
Comparison of the two structures, one obtained at ~pH 5.5
(2.5 Å, PDB 6P8I) and the other at pH ~7.0 (2.8 Å, PDB 6V02),
reveals the same domain orientations relative to one another, an
inverted “T” (Fig. 1b and Table 1). Interestingly, both conditions
show evidence of the N-glycan at N591 of a crystallographic
neighbor partially occupying the carbohydrate-binding site of
domain 5. The pH 5.5 structure had sufficient occupancy to allow
carbohydrate refinement while the corresponding region in the
pH 7.0 structure did not (Fig. 1b). The other CRD (domain 3)
remains unoccupied in both structures, unlike bovine CI-MPR
domains 1–3, where we showed domain 3 was bound to a ligand:
either M6P or the oligosaccharide of a crystallographic neighbor
(Fig. 1c, inset)24,25. Although we were surprised that the domain-
3 binding pocket did not contain M6P at pH 7.0 conditions, the
presence of the N-linked glycan near the binding site of domain 5
could perturb conformational equilibria between substructures
that stabilize a domain arrangement most favorable for crystal-
lographic packing. Due to the higher resolution and greater
degree of completeness, we focus our analyses on the pH
~5.5 structure (PDB 6P8I). The current structure of domains 1–5
allows us to evaluate the consequence of carbohydrate binding to
a single CRD on individual domain structures and the overall
positioning of domains relative to one another.
A comparison of domains 1–3 of PDB 1SYO (ligand-bound
domain 3) to the N-terminal three domains of the current structure
of human domains 1–5 (PDB 6P8I, ligand-free domain 3, ligand-
bound domain 5) reveals individual domains retain their overall
core structure (r.m.s.d. < 0.5 Å). However, a substantial change in
the quaternary structure occurs, with an ~45° rotation and 34- Å
movement (S386 in loop C) of domain 3 (Fig. 1c). The interdomain
linker between domains 2 and 3 adopts a more extended structure
in the absence of ligand, allowing for the repositioning of domain 3
(Fig. 1c). The ability to alter conformations of this 9-residue linker
region appears to be an essential factor in the relocation of domain
3, and its important role is supported by the high species
conservation of amino acids (ConSurf26) within this region
(Supplementary Fig. 1). In the absence of a ligand bound to
domain 3, its C-terminal face contacts the C-terminal face of
domain 1 (Fig. 1e). However, upon ligand binding to domain 3, this
domain straddles the C-terminal face of domain 1 and the
N-terminal face of domain 2 (Fig. 1e). The position of domain 2
relative to domain 1 does not experience a comparable change as
domains 1 and 2 overlay closely (Fig. 1c). Together, these findings
show that the presence of ligand alters the nature of the relationship
of domain 3 to its neighboring domains illustrating the dynamic
nature of this N-terminal region of CI-MPR.
Comparison of structures of the two P-type lectins. CI-MPR
and CD-MPR are the sole members of the P-type lectin family2.
CD-MPR is a homodimer with a single MRH domain per poly-
peptide. CD-MPR transitions in a scissoring-like motion from a
closed (binding sites closer together), smaller dimer interface to
an open (larger distance between binding sites) conformation in
the presence of M6P (Supplementary Fig. 2a)27. These
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movements triggered by ligand binding increase the size of the
interface and add salt bridges, but create an energetically less
favorable association (Complex Formation Significance Score as
calculated by PISA28) (Supplementary Fig. 2b). In contrast,
domain 3 of the multidomain CI-MPR has a composite interface
made up of interactions with domains 1 and 2. Rearrangement of
domain 3 upon binding ligand reorients its C-terminal β-sheet
facilitating communications with both domains 1 and 2, altering
salt bridge contacts and reducing the interface (Fig. 1e and
Supplementary Fig. 2b).
Despite these two receptors differences, multidomain versus
homodimeric, they have significant similarities in their manner of
ligand binding. Both receptors use residues located on flexible
loops to generate salt bridges with the neighboring domain(s) and
hydrophobic cores comprised of residues within the C-terminal
β-sheet. CD-MPR maintains a back-to-back (C-terminal β-sheet
of one monomer against the C-terminal β-sheet of the other
monomer) arrangement in both ligand-bound and unbound
states (Supplementary Fig. 2a, c), whereas the domain 1 to
domain 3 back-to-back arrangement of CI-MPR is found only in
the ligand-unbound state (Fig. 1c).
Conformation of CI-MPR bound to a lysosomal enzyme.
Because we were unable to obtain crystals of CI-MPR domains
1–5 with an alternate ligand binding scenario, we turned to SAXS.
This technique allowed us to gather information on overall pro-
tein structure and the effects of (1) ligand binding to domain 3,
and (2) ligand absence in domain 5. Although SAXS provides
lower resolution data and represents a global average of structures
in solution, it has proven to be a robust method to explore bio-
molecular shapes as well as conformational changes under phy-
siological conditions29. We collected SAXS data at pH 6.5 in the
absence and presence of M6P or PPT1, both of which interact
preferentially with the phosphomonoester-specific binding site of
domain 317,30. Data from the domains 1–5 protein produced
hyperbolic Kratky plots, characteristic of globular proteins with
some tailing indicative of the presence of protein flexibility
(Supplementary Fig. 3a). The curves did not significantly change
in the presence of either ligand (Supplementary Fig. 3a). In
addition, SAXS data, whether collected in the presence or absence
of ligand, produce a Porod exponent (PE) of 2.8–2.9 that is
indicative of a flexible protein with perhaps some intrinsic dis-
order (Supplementary Fig. 3b, c)29.
Fig. 1 The structure of the N-terminal domains of CI-MPR in the presence and absence of ligand. a Cartoon of the domain structure of CI-MPR, highlighting
the multifunctionality of the protein. Relevant ligands are listed next to their known domain of interaction. Domains with no known function to date are
colored gray. b Overlay of Cα atoms (r.m.s.d. of ~0.2 Å over 524 Cα atoms) of models of crystal structures solved at pH 5.5 (PDB 6P8I) and 7.0 (tan) (PDB
6V02). MRH domains are labeled (d1-d5) along with the N- and C-termini. The red circle marks the unoccupied known M6P binding site in domain 3, while
the glycan of a crystallographic neighbor occupying the known binding site of domain 5 (PDB 6P8I) is circled in black. The covalently attached glycan at
N591 is shown in stick representation. Approximate dimensions of the domains 1–5 model are given. Inset shows the 2fo-fc map (contoured to ~0.7σ)
around N591 of a crystallographic neighbor. c Overlay of the Cα atoms of domain 1 of PDB 1SYO (M6P bound domain 3) (gray) with those of PDB 6P8I
(unbound) (green). Residue S386 of loop C is labeled in the unbound (black spheres) and bound (red spheres) structures. The linker between domains 2
and 3 of PDB 6P8I is shown in black while that of 1SYO is shown in red. The rotated inset shows only domain 3 of each structure. The carbohydrate-binding
sites are circled in red. The bound M6P (PDB 1SYO) is shown in yellow sticks. d A comparison of the known domain 3 structures bound to oligosaccharide
of neighbor (pink, PDB 1Q25), M6P (protein by gray cartoon and M6P in yellow sticks, PDB 1SYO), or unbound (green, PDB 6P8I). Displacement of the
atoms S386 (2.9 Å) and S387 (2.6 Å) of loop C in the absence of ligand is shown. The four residues essential for carbohydrate binding are labeled. e The
change in regions of side-chain interactions between domain 3 and domains 1 and 2 upon ligand binding to domain 3 is circled in black.
COMMUNICATIONS BIOLOGY | https://doi.org/10.1038/s42003-020-01211-w ARTICLE
COMMUNICATIONS BIOLOGY |           (2020) 3:498 | https://doi.org/10.1038/s42003-020-01211-w | www.nature.com/commsbio 3
We then calculated three-dimensional (3D) ab initio models of
domains 1–5 in the absence and presence of ligand and compared
them to our crystallographic models. The overall shapes of the
calculated envelopes in the presence or absence of M6P are
similar (Supplementary Fig. 3d and Fig. 2a), resembling a sock
with a dimple near the heel. Because M6P is too small to be
identified by SAXS, we also utilized the human lysosomal enzyme
PPT1. This recombinant, monomeric 279-residue protein harbors
three N-linked glycans, and the crystal structure of a monomeric
form has already been determined31. PPT1 alone gives rise to an
oblong 3D model and its position is easily discernable in complex
with domains 1–5 (Fig. 2b, c). Based on its preference for the
phosphomonoester binding site of domain 3, the envelope is
consistent with PPT1 binding to CI-MPR’s domain 3 through its
M6P-containing glycans. The molecular weight calculated from
the envelope volume (MW, (in kDa)= Vp (in nm3)/1.632)
(Supplementary Fig. 3c) supports the 1:1 stoichiometry of the
complex. Inspection of the 3D envelopes of domains 1–5 bound
either to PPT1 (Fig. 2c) or M6P (Supplementary Fig. 3d) shows
lack of molecular model (composite model of human domain 1–5
with ligand bound to domains 3 and 5) in the toe region. This
absence of model is consistent with domain 5, and perhaps
domain 4, residing in a different location than found in our
crystallographic structure (PDB 6P8I). Supporting this notion is
the observation that domain 4 in our crystallographic structures
appears flexible, as demonstrated by discontinuous density,
especially in the pH 7.0 structure (PDB 6V02). The flexibility of
domain 4 was also recently demonstrated in the cryo-EM
structures published by Wang et al.22 at the time of this paper’s
submission. Comparing their bovine domains 4–14 structure at
pH 7.4 in the presence of IGF2 with our human domains
1–5 structure at pH 5.5 or 7.0 shows domain 4 rotated ~180°
(Supplementary Fig. 3e).
We next used the program MultiFoXS to model possible
orientations of domains 5 and 4 to improve the fit of our model to
the SAXS scattering curves (Fig. 2d, see “Methods” for details of
model generation)33. Starting with the simplest scenario, only
allowing flexibility of the linker between domains 4 and 5, an
improved model was calculated with domain 5 swinging into the
unpopulated “toe” region (~60 Å) (Supplementary Fig. 3f). Next,
we allowed flexibility between both domains 3 and 4 as well as
domains 4 and 5 (Fig. 2e). In this model, domain 5 has translated
into the toe of the SAXS envelope accompanied by the relocation
of domain 4. Allowing either domain 5 or domains 4 and 5 to be
flexible and assume alternate conformations from our crystal
structure improved the χ2 of the model fit to the scattering curve
from 6.62 to 1.47/1.97 (Fig. 2d, e). Together, these SAXS data
(Fig. 2d, e, Supplementary Fig. 3f) are consistent with our
hypothesis that domains 4 and 5 are flexible and exist in alternate
conformations in the absence of ligand bound to domain 5.
To examine the extent of motions these domains undergo, we
negatively stained domains 1–5 in the presence and absence of
M6P at pH 7.4 and imaged the samples by electron microscopy
(EM). The reference-free 2D classifications yielded 50 classes of
domain arrangements in the absence of M6P (Fig. 3). The
diversity in the negatively stained EM images demonstrates how
dynamic this region of CI-MPR is in the absence of ligand.
Although the binding of M6P to domain 3 reduces the number of
classes, indicating an overall reduction in domain mobility upon
binding, there are still numerous classes representing multiple
conformations of domains 1–5. Together, these SAXS and EM
data indicate a high degree of flexibility of CI-MPR’s N-terminal
five domains. However, when domain 5 tethers to the C-terminal
domains 6–15 in the native structure, its mobility may be
constrained in the context of the full-length receptor.
Adjacent domains required to achieve high-affinity binding.
Our previous studies examining individual CRDs demonstrated
that they bind specifically to ligand but with a lower affinity than
in a multidomain construct. For example, domain 3 bound the
lysosomal enzyme β-glucuronidase with ~1000-fold lower affinity
than domains 1–3 (KD= 500 versus 0.5 nM)34,35, which could be
explained from our crystal structure of domains 1–3 (PDB 1SYO)
where interdomain interactions, particularly with domain 1, sta-
bilize the binding pocket of domain 319,24. In contrast, domains 4
and 5 have a minimal effect on the phosphomonoester-specific
binding activity of domain 3 (Supplementary Fig. 4a–c). Results
of surface plasmon resonance (SPR) analyses show domains 1–3,
domains 1–5, and domains 1–5R688A (mutation of R688 pre-
viously shown to eliminate carbohydrate binding to domain 530)
have similar affinities toward the lysosomal enzyme PPT1 (Sup-
plementary Fig. 4d–f). PPT1 contains phosphomonoester N-gly-
cans predominately (Supplementary Fig. 4g–i). Thus, the
domains 1–3 construct is sufficient to convey high-affinity
binding, and domains 4 and 5 are not required for proper
carbohydrate-binding function.
We used SPR in conjunction with the lysosomal enzyme acid
α-glucosidase (GAA) (modified to contain only phosphodiesters
on its N-glycans) to evaluate domain 5’s ability to bind
phosphodiesters specifically30. The presence of the additional
four N-terminal domains significantly increases the affinity of
domain 5 for GAA phosphodiester (KD= ~60 nM) (Fig. 4), which
is an ~150-fold higher affinity than we previously showed for a
construct encoding domain 5 alone17. We reported a similar
finding of increased binding affinity (~60-fold) comparing a
construct encoding domains 5–9 with that of domain 5 alone17.
Our NMR solution studies on domain 5 alone20 demonstrates
that this domain is stable and capable of specific ligand
Table 1 Data collection and refinement statistics (molecular
replacement).
pH 5.5 (PDB 6P8I) pH 7.0 (PDB 6V02)
Data collection
Space group P 1 21 1 P 1 21 1
Cell dimensions
a, b, c (Å) 50.8 66.2 123.1 50.8 66.2 124.5
α, β, γ (°) 90 99.2 90 90 100.5 90
Resolution (Å) 40.0–2.5 (2.63–2.54) 35.9–2.80 (2.90–2.80)
Rmerge 0.072 (0.62) 0.058 (0.54)
I/σI 18.4 (2.13) 14.8 (1.87)
Completeness (%) 98.4 (91.0) 90.5 (42.4)
Redundancy 3.7 (3.4) 2.0 (2.0)
Refinement
Resolution (Å) 40.0–2.5 (2.63−2.54) 35.9–2.8 (2.90−2.80)


















Bond lengths (Å) 0.007 0.007
Bond angles (°) 1.30 1.28
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recognition. As expected, domains 1–5 bound with high affinity
to the lysosomal enzyme GAA modified to contain phosphodie-
sters or phosphomonoester, and PPT1 (Fig. 4). These data are
consistent with the hypothesis that additional domain(s)
contribute to the high-affinity binding of domain 5 through
protein–protein interactions that serve to stabilize the binding site
or through the presence of a secondary binding site(s).
We next evaluated if there were allosteric interactions between
CRDs: does carbohydrate binding to one CRD (domain 3) affect
ligand binding to the second CRD (domain 5). For these SPR
studies, increasing concentrations of domains 1–5 were preincu-
bated with a fixed concentration of PPT1. These solutions were
flowed over a sensor chip immobilized with GAA phosphodiester,
GAA phosphomonoester, or PPT1. The resulting sensorgrams were
analyzed and displayed by double reciprocal plots (Fig. 4d–f). The
resulting plots indicate that PPT1 competitively inhibits phospho-
monoester ligand binding to domains 1–5. When the receptor-
PPT1 complex (PPT1 prebound to domain 3 leaving domain 5
unbound) flowed over a GAA-phosphodiester surface, similar
results to those obtained for the phosphomonoester surfaces were
observed (Fig. 4) signifying PPT1 can inhibit phosphodiester
binding. One explanation is that PPT1 binds to domain 3 and
sterically blocks domain 5 from binding GAA phosphodiester.
However, this possibility seems unlikely based on SAXS data: we
observed the envelope for PPT1 (bound to domain 3) is elongated
and points away from the N-terminus and the rest of the receptor
(Fig. 2c): PPT1 is not in contact with domain 5. Another possibility
is that PPT1 binding to domain 3 causes a rearrangement of
domains such that the binding site of domain 5 is no longer
accessible by ligand. This latter possibility of allosteric interactions
between the CRDs is consistent with our crystal structures that
illustrate that domain interactions can be dramatically altered in the
presence or absence of ligands, such as between domain 3 and
domains 1 and 2 (Fig. 1c, d). Protein footprinting studies were used
to investigate this hypothesis (see below).
Mapping PPT1 interactions. To further interrogate receptor-
PPT1 interactions, we turned to HRPF utilizing fast photo-
chemical oxidation of proteins (FPOP)36 as a method to compare
protein topography between two structural states (e.g., ligand-
bound versus ligand-free). Briefly, proteins are allowed to react
with a high concentration of very short-lived hydroxyl radicals
generated in situ. Hydroxyl radicals diffuse to the surface of the
protein, where they oxidize amino acid side chains forming stable
protein oxidation products at the site of oxidation. The rate of
this oxidation reaction is directly proportional to the solvent
accessible surface area of the amino acid. Changes in amino acid
accessibility at the protein surface can be localized and measured
by monitoring the rate of reaction of these surface amino acids:
occlusion of that portion of the protein surface results in a
decrease in the apparent rate of oxidation, while exposure of that
portion of the protein surface results in an increase in the rate of
oxidation37. These stable oxidation products are measured
through liquid chromatography-tandem mass spectrometry (LC-
MS/MS)38. FPOP analysis of the changes in the topography of
Fig. 2 Ab initio envelope models rendered as volumes and superimposed onto X-ray crystallographic models. a X-ray model (PDB 6P8I) placed within
envelope derived from SEC-SAXS data of domains 1–5 collected in the absence of b PPT1 (PDB 1EI9). The three Asn residues that are glycosylated are
shown as spheres (circled in black). c The modified X-ray model of domains 1–5 (gray), representing domain 5 in the bound position with the PPT1 model
(red) (PDB 1EI9) placed within the calculated ab initio envelope (rendered as a volume illustrating extra density along the most elongated axis).
d Experimental scattering curve for domains 1–5 (black) overlaid with calculated scattering curves generated from X-ray model (PDB 6P8I, red) or
MultiFoXS-generated model based on PDB 6P8I where either the linker between domains 4 and 5 (yellow) or linkers between both domains 3 and 4 and
domains 4 and 5 (cyan) are allowed to be flexible. e MultiFoXS-4–5 (cyan line in d) derived model of domains 1–5 in the absence of ligand placed in the
same envelope as in a showing relative movements (20 Å) of domains 4 (gray, PDB 6P8I, to orange) and 5 with N682 moving 37 Å (cyan, PDB 6P8I, to
red). Corresponding χ2 value for the curve is shown in a and e.
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CI-MPR domains 1–5 upon the addition of PPT1 reveals three
regions of change distributed over 4 of the 5 domains (Fig. 5a and
Supplementary Fig. 5a). PPT1 binding: (1) occludes highly species
conserved regions (Supplementary Fig. 1) of the interface between
domains 1 and 3, including loop C (previously identified as being
part of the high-affinity carbohydrate-binding site) (Fig. 5b24), (2)
occludes the C-terminal region of front β-sheet (strands 2–4) of
domain 5 (Fig. 5c); (3) causes domain 4 to exhibit a topographical
rearrangement resulting in occlusion of some surfaces and
exposure of others (Fig. 5d and Supplementary Fig. 5b–d).
Together, these findings demonstrate a binding-induced con-
formational change of CI-MPR. Because the interaction of PPT1
with domains 1–5 occurs with a 1:1 stoichiometry (Supplemen-
tary Fig. 3c), supported by SPR analyses showing only one CRD
can be engaged in ligand binding at a time (Fig. 4), these data are
consistent with PPT1’s phosphomonoester-containing N-glycans
binding to domain 3 causing a reorientation (allosteric) of
domains such that domain 5 is no longer able to bind ligand
(Supplementary Fig. 5d).
Evidence for a secondary carbohydrate-binding site. Two pep-
tides in domain 3 experience decreased oxidation rates upon the
addition of PPT1, indicating a decrease in their solvent accessi-
bility (Supplementary Fig. 5e–f). Peptide 370–391 is located in the
M6P binding site of domain 3 and contains residue R391 that is
highly conserved and is essential for high-affinity M6P binding.
The observed decreased oxidation rate of peptide 370–391 is
consistent with PPT1 binding to this region of the receptor and
altering solvent accessibility to hydroxyl radicals. The second
peptide, 91–101, is located on β-strand 7 on the C-terminal β
sheet of domain 1. As shown in our crystal structures of domains
1–3 bound to carbohydrate, domain 1’s β-strand 7 resides across
from domain 3’s M6P binding site (Supplementary Fig. 5e–f).
Although this peptide in domain 1 is outside the known M6P
binding region in domain 3, its proximity coupled with its altered
oxidation rate upon PPT1 binding raises the possibility it func-
tions as part of a secondary site of carbohydrate interaction. The
existence of a secondary, lower affinity binding site is consistent
with SPR analyses that showed high and moderate binding affi-
nities for CI-MPR domains 1–3 upon PPT1 binding (Fig. 4a–c
insets).
In silico approaches were used to further explore this
possibility of a secondary binding site independent of a known
CRD. Initial docking experiments on the modified (bound
domain 3, unbound domain 5) crystal structure of domains 1–5
Fig. 3 Negative-stain electron microscopy of domains 1–5 of CI-MPR in the absence and presence of M6P. a A survey of a negative-stain TEM image of
the sample of CI-MPR domains 1–5 in the absence of 10-mM M6P. b Six representative images of reference-free class averages of the particles of CI-MPR
domains 1–5 in the absence of 10-mM M6P. c Six representative class average images of the particles of CI-MPR domain 1–5 selected from a pool of 35
representative reference-free class averages in the presence of 10-mM M6P. d A survey of a negative-stain TEM image of the sample of CI-MPR domains
1–5 in the presence of 10-mMM6P. e Six representative images of reference-free class averages of the particles of CI-MPR domains 1–5 in the presence of
10-mMM6P. f Six representative class average images of the particles of CI-MPR domain 1–5 selected from a pool of 35 representative reference-free class
averages in the presence of 10-mM M6P.
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used the FTMap server to identify possible small molecule
interaction sites (Fig. 6a)39. One of the identified “hot spots”
overlaps with the species conserved region of peptide 91–101 of
domain 1’s β-strand 7 determined by HRPF (Supplementary
Fig. 5e, f). Inspection of the X-ray structure (PDB 1EI9) revealed
that PPT1’s three N-glycans clustered close to each other, and
molecular dynamics (MD) simulations demonstrate the inherent
flexibility of glycans (Fig. 6b). Lyly et al. had previously shown
that the glycan on N232 is critical for the proper trafficking of
PPT1 to the lysosome40. Docking of the glycan on N232 into the
binding site of domain 3 allows the glycan of N212 to be near the
“hot spot” described above, strand 7 of domain 1, introducing a
low-affinity interaction site with domain 1 (Fig. 6c). Further
support of the receptor’s bidentate binding arising from
interactions with two individual oligosaccharides rather than
with multiple arms of the same oligosaccharide comes from the
work of Yamaguchi et al.41. This group utilized an engineered
disulfide bridge containing glycopeptide comprised of two M6P-
containing glycans. This peptide bound to CI-MPR with a higher
affinity in the absence of reducing agent than in the presence41.
Lysosomal enzymes typically possess multiple glycosylation sites,
like PPT1. Some of these enzymes, such as β-glucuronidase, do so
via oligomerization. This tetrameric protein, with four N-glycans
per monomer42, presents a more expansive spatial array of
phosphorylated glycans that together can enhance the engage-
ment with CI-MPR’s CRDs to obtain high-affinity binding via
multivalent interactions. The existence of low-affinity binding
sites, such as that proposed above in domain 1, would enhance
the avidity of these interactions.
CI-MPR undergoes domain rearrangement at endosomal pH.
Recognition and binding of lysosomal enzymes by CI-MPR
represent only the first part of this receptor’s function. The
receptor must also releases its cargo in the acidic pH environment
of the endosome (~pH 5). This release process is critical since the
neutralization of intracellular compartments results in excessive
secretion of lysosomal enzymes, with MPRs being “trapped” with
their cargo1. Size-exclusion chromatography (SEC) of three
constructs (domains 1–15, 1–5, and 7–15) shows that as the pH
becomes more acidic, CI-MPR exhibits a more compact Stokes
radius (Fig. 7a). To determine if changes in Stokes radius localize
to one region of the receptor over another, we normalized the
change in Stokes radius for each construct against the number of
domains in the construct. Normalization clearly shows that the
N-terminal 5 domains undergo the most substantial change in
radius: they compact on each other the most (Fig. 7b). We again
turned to HRPF to evaluate conformational changes of CI-MPR
as a consequence of pH. This technique was shown previously to
be free of pH-induced secondary effects and used to map the pH-
induced structural changes of Protein G43. When applied to our
system, analysis of HRPF results shows widespread changes in the
conformation of domains 1–5 upon a change in pH from 6.5 to
4.5, with the changes more extensive than that observed upon the
addition of PPT1 (Figs. 5a, 7c, and Supplementary Fig. 6). The
increase in the areas of protection from oxidation upon acid-
ification is (1) consistent with SEC data, and (2) demonstrates
that CI-MPR undergoes significant domain rearrangement and
compaction of its overall conformation. In addition, the two
peptides (91–101 and 370–391) observed to gain protection from
oxidation in the presence of PPT1 (Supplementary Fig. 5a) report
higher degrees of modification in transitioning to acidic pH
(Supplementary Fig. 6a), a finding consistent with ligand release
and exposure of these peptides to solvent in the acidic environ-
ment of endosomes.
Concurrent with submission of this manuscript, Wang et al.
published the cryo-EM structures of endogenous CI-MPR from
bovine liver at both pH 4.5 and bound to IGF2 at pH 7.422.
However, the structure of domains 1–3 and domain 15 in the
IGF2 bound cryo-EM structure at pH 7.4 was unable to be
Fig. 4 Ligand binding properties of domains 1–5 as assessed by SPR. Sensorgrams of domains 1–5 truncated protein (10, 15, 20, 30, 40, 50, 60, 70, 80,
90, 100, 110, and 120 nM) flowing over GAA-phosphomonoester (a) or GAA phosphodiester (b) and PPT1 (c) surfaces. Inset graphs show Scatchard plots
based on average RU value collected over 10-s time intervals at the end of the association phase for each concentration of domains 1–5 (red bar). The
calculated KDs (−1/slope) values for two binding events are listed and n= 4 independent experiments (standard error of mean is reported). Results from
the accompanying competitive inhibition study are displayed as double reciprocal plots (d–f) in which domains 1–5 protein (at 10, 15, 20, 30, 40, 50, 60,
70, 80, 90, 100, 110 or 120 nM concentration) was preincubated for 2 h with 0, 40, 80, or 100-nM PPT1 (as indicated in d) before being flowed over the
three different lysosomal enzyme surfaces as indicated in a–c.
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discerned. Comparison of domains 1–5 from the X-ray structure
reported here (collected at pH 5.5 with a ligand bound to domain
5 (PDB 6P8I)) and the cryo-EM structure of endogenous CI-MPR
completely ligand-unbound (PDB 6UM1) at pH 4.5, reveals an
overall similarity with a calculated r.m.s.d. of 1.3 Å over 512 Cα
atoms. However, overlaying the corresponding Cα atoms of
domain 1 (r.m.s.d. of 0.7 Å) provides a clearer picture of the
structural differences between the two pH values (Fig. 7d).
Domains 1 and 3, as well as domains 1 and 2, retain their
association as assessed by the preservation of their
domain–domain interfaces as well as minimal changes in the
number of salt bridges and hydrogen bonds whether ligand is
bound to domain 5 or the receptor is at low pH (Supplementary
Fig. 6b). The most obvious difference between the two structures is
the location of domain 4 relative to the other domains (Fig. 7d, e).
It is noteworthy that the position of domain 4 at pH 4.5 is
consistent with its predicted position calculated from the
unbound SAXS data (Fig. 2e). In addition, when the FPOP data
are mapped onto domains 1–5 of the cryo-EM structure
determined at pH 4.5 (PDB 6UM1), the protection of peptides
located on strands 1 and 2 of domain 4 is consistent the
relocation of domain 4 (Fig. 7f). Furthermore, the position of
domain 5 is very similar whether it is bound to ligand (PDB 6P8I)
or at low pH (PDB 6UM1) and adopts an alternate position
(based on our SAXS data), on average, at higher pH values or in
the absence of ligand. This is in contrast to the other CRD of the
domain 1–5 construct, domain 3, which assumes an alternate
conformation when bound to ligand (Fig. 2e). Domain 3 assumes
the same orientation whether unbound (PDB 1SYO) (at higher
pH conditions favorable for ligand binding) or at the lower pH
required for ligand release, pH 4.5 (PDB 6UM1).
Discussion
Our X-ray crystal structures, coupled with SAXS, FPOP, and SPR
analyses, allows us to propose an allosteric mechanism for the
functioning of CI-MPR. Allosteric mechanisms rely on an intri-
cate network of atomic interactions to convey binding status at
one site to spatially remote sites. In the case of CI-MPR, domain 3
plays a pivotal role in this receptor’s carbohydrate binding to
either domain 3 or 5, facilitating a change in domain orientation,
either blocking ligand accessibility or altering the stability of the
binding pocket. The orientation of domain 3 of the domains 1–5
protein construct appears to be carefully regulated by a series of
non-covalent interactions (Supplementary Fig. 7a–d). These loop
and domain interface changes allow for the passage of informa-
tion regarding ligand binding status at one CRD to another CRD
through an intricate non-covalent chemical network: relaying
information from one region of the molecule to a more distant
region through an allosteric mechanism.
This common theme of allosteric regulation of ligand binding
extends to another CI-MPR ligand: the non-M6P-containing
Fig. 5 FPOP analysis of domains 1–5 in the absence and presence of PPT1
at pH 6.5. a FPOP comparison of domains 1–5 alone and in the presence of
PPT1 reveals peptides protected (red shaded region and colored by domain:
d1, blue; d2, magenta; d3, green; d4, orange; or d5, cyan) or exposed (green
shaded region and colored by domain) upon binding, while most peptides
(black circles) show no statistically significant (p≤ 0.05) changes
(unshaded region). b Comparison of peptides (dashed black ovals)
(mapped onto SAXS-generated model of bound domain 3 and unbound
domain 5) undergoing changes in oxidation in the absence and presence of
PPT1 ligand (red mesh and ribbon, peptides more protected, green mesh
and ribbon, peptides less protected in the presence of PPT1, gray spheres,
no data available). Ligand binding loop C is circled. c Domain 5 peptides
showing protection from oxidation in the presence of PPT1 mapped onto
the model in b (dashed black ovals). β strands affected are labeled.
d Peptides in domains 4 (orange dashed oval) and 5 (cyan dashed oval)
showing changes in exposure and protection in the presence of PPT1
mapped onto the current model of domain 5 being ligand-free and domain 3
ligand bound. The arrow indicates the possible movement of domain 5,
which would result in the protection of both peptides and produce an
overall molecular shape consistent with SAXS data.
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peptide, IGF2, in which contacts with domain 13 enhance the
binding affinity of domain 11 for IGF2 by ~tenfold44. In addition,
inspection of the cryo-EM structure of bovine CI-MPR bound to
IGF2 suggests allosteric regulation extends to the interplay
between domain 11 and domain 9. When domain 11 is bound to
IGF2, the M6P binding pocket of domain 9 is blocked and
inaccessible to ligand binding (Fig. 8a). However, when the
receptor is exposed to pH 4.5 conditions, domain 9 changes its
relative position fully exposing its carbohydrate-binding site to
solvent (Fig. 8b). These changes in the orientation of domain 9
dependent upon the binding status of domain 11 further
demonstrate the allosteric behavior of this receptor. Furthermore,
because domains 1–3 as well as domain 15 could not be identified
in the IGF2 bound structure (PDB 6UM2) due to their high
mobility22, the effect of IGF2 binding on the other CRDs is
unknown.
To our knowledge, we are reporting the first structural view of
a complex between CI-MPR and a lysosomal enzyme, PPT1. This
information provides insight for future studies into developing a
therapy for newborns with infantile neuronal ceroid lipofusci-
nosis who are deficient in this enzyme. Recent studies by
Amaravadi et al. showing PPT1-dependent depalmitoylation
stabilize the lysosomal localization of v-ATPase subunits, which
directly impacts lysosomal acidification needed for autophagic
processes and mTOR signaling, further emphasizes the need for
proper MPR-mediated delivery of PPT1 to the lysosome45. In
addition, FPOP and SPR data lead us to refine our model of
carbohydrate binding by domains 1–5 of CI-MPR to include the
interaction of a second oligosaccharide with a neighboring
domain.
To fully understand how ligand binding regulates CI-MPR
structure and function, additional studies are needed to address
several unanswered questions. Does lysosomal enzyme binding
elicit allosteric effects on CI-MPR’s non-M6P-containing ligands,
IGF2, plasminogen, and uPAR? Conversely, do these non-M6P-
containing ligands modify the carbohydrate-binding activity of
one, several, or all four of CI-MPR’s CRDs? Do the receptor’s C-
terminal 10 domains impact the conformational dynamics of the
N-terminal five domains? Concerning the pH-dependent release
of ligand, we observed construct-specific behaviors during pur-
ification over a PPT1 affinity column. Constructs containing the
N-terminal domains 1–3 or 1–5, along with domains 1–15, eluted
efficiently from the column upon reducing the buffer pH to 4.5,
unlike the domains 7–15 construct that required M6P for elution
(Supplementary Fig. 8). These findings correlate with the obser-
vation that CI-MPR’s domains 1–3, but not domains 7–9 or 7–11,
eluted from a pentamannosyl phosphate-agarose column at pH
4.646. It is intriguing to speculate that the N-terminal 5 domains
play a predominant role in regulating CI-MPR’s ability to bind
and release its diverse ligands. In conclusion, CI-MPR function
appears to be under allosteric regulation, and future studies are
needed to advance our understanding of domain interplay for this
conformationally dynamic receptor.
Methods
Generation and expression of human CI-MPR constructs. DNA sequences
corresponding to domains 1–3 (residues 1–433), 1–5 (residues 1–726), 7–15
(residues 888–2296), and 1–15 (residues 1–2296) (numbering does not include the
N-terminal signal sequence (residues 1–35) of the human CI-MPR were amplified
directly from the human clone (GeneBank Accession No. J03528) obtained from
the American Type Culture Collection (pGEM-8 ATCC 95661) using standard
polymerase chain reaction methods. Mutant cDNAs (R391A and R688A) were
generated using DpnI-mediated site-directed mutagenesis and confirmed by DNA
sequencing. All constructs were cloned into pVL1392 modified to contain the
native bovine CI-MPR N-terminal signal sequence followed by a NotI sequence
and a C-terminal thrombin, hexahistidine, an Avi tag, and XbaI and used to
generate Baculovirus using the BestBac method (Expression Systems). Spodoptera
frugiperda (Sf9) cells (Expression Systems) were infected with baculovirus at a
density of 3.0 × 106 cells per ml for 96 h at 27 °C in ESF 991 with 1% Production
Boost Additive added after 24 h. Cells were removed from the medium by cen-
trifugation at 1000 g.
Purification of human CI-MPR domains 1–5 protein for PDB 6P8I. The media
was concentrated to ~40 ml using Amicon stir cells before dialysis against three
Fig. 6 Possible secondary site of oligosaccharide interaction. a Small
molecule “hot spots” identified through the use of the FTMap server
(http://ftmap.bu.edu/login.php) are shown (colored stick representation)
on the model of domains 1–5 bound to a ligand in domain 3. Region of
predicted small molecule interaction near secondary site proposed from
analysis of FPOP data is circled in dashed black line. Loop C of the M6P
binding site (circled in dashed red line) is labeled (domains are colored d1,
blue; d2, magenta; d3, green). b Molecular dynamics simulations were used
to map the extent of movement the 3 N-linked glycans of PPT1 can undergo
(mannose moieties are represented by green spheres while blue boxes are
used to represent GlcNAc). c PPT1 (PDB 1EI9) (red) structure is overlaid on
the model of domains 1–5 (dark gray) with domain 3 bound and domain 5 in
the unbound position with the oligosaccharide on N232 of PPT1 resting near
Loop C (binding site) of domain 3. The oligosaccharide on N212 of PPT1 is
located near strand 7 (magenta) of domain 1. Small molecule “hot spots”
are circled in dashed black line. Mannose moieties are represented by green
spheres while blue boxes are used to represent GlcNAc.
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times 4 L of 20-mM Tris, pH 7.5 at 22 °C, 150-mM NaCl. Protein solutions were
centrifuged at 20,000 g to remove particulate matter before loading on 5-ml Ni-
NTA columns. The resin was washed with 20-mM Tris pH 7.6, 300-mM NaCl, and
20-mM imidazole before elution with 20-mM Tris pH 7.6, 300-mM NaCl, and
100-mM imidazole. Fractions were analyzed by SDS-Page, pooled, and con-
centrated to 1 mg/ml before overnight dialysis at 4 °C into 20-mM Tris, pH 7.6 at
22 °C, 150-mM NaCl. C-terminal tags were removed by incubation overnight at
4 °C with Thrombin (Sigma). Thrombin was removed by passage over benzamidine
agarose beads. Protein was incubated overnight with PNGaseF to remove N-linked
glycans followed by passage over Ni-NTA agarose to remove His-tagged PNGaseF.
Domains 1–5 protein was then passed over a 10/300 Superdex G200 column
equilibrated in 20-mM Tris pH 7.4 at 22 °C, 150-mM NaCl to remove any
remaining aggregates or contaminants.
Crystallographic studies for PDB 6P8I. Protein was concentrated to 7 mg/ml and
incubated with 10-mM M6P and 10-mM MnCl2. Initial crystallization hits were
found with Molecular dimensions JCSG-plus. Optimization was carried out using
the hanging drop method of vapor diffusion in 24-well Falcon plates with 500 μl of
well solution (100-mM ammonium citrate dibasic, pH 5.5, 20% PEG 3350) at
19 °C. Protein solution was dispensed on cover slips in a 1:1 ratio with well
solution. Crystals appeared in greater than a week. Crystals were cryoprotected in
reservoir solution+ 25% glycerol and frozen in liquid nitrogen. Data were collected
at 1.54 Å using a Rigaku M007 generator equipped with Osmic mirrors and an R-
AXIS IV++ detector. Data were processed and scaled with HKL2000 software47.
Purification of human CI-MPR domains 1–5 for PDB 6V02. Protein was pre-
pared as described above except without PNGaseF digestion and additional pur-
ification over a 5-ml pentamannosyl phosphate-agarose affinity column19
equilibrated in 50-mM imidazole, pH 6.5, 150-mM NaCl, 5 mM β-glycerol
phosphate. Protein was eluted by the addition of 10-mM M6P to column buffer.
Crystallization studies for PDB 6V02. Protein was concentrated to 7 mg/ml and
incubated with 10-mM MnCl2. A crystallization hit was identified using Molecular
dimensions JCSG-plus (100-mM HEPES, 30% Jeffamine ED-2003) after more than
1 week at 19 °C (sitting drops with 1:1 ratio of protein (0.15 μl) to well solution
(60 μl in well). Crystals were cryoprotected in reservoir solution+ 20% glycerol and
frozen in liquid nitrogen. Data were collected at 1 Å at APS beamline 17-ID
(IMCA-CAT) at 100° K, processed using autoPROC48.
Structure determination of human CI-MPR domains 1–5. Phases for the pH 5.5
conditions structure were determined by Phaser in CCP4i49 using homology
models generated using the Swiss-Model server. The model was iteratively refined
using PHENIX50 and manually rebuild in COOT51 and showed reasonable ste-
reochemistry, with 85.5% in the Ramachandran favored zones, 11.3% in the
allowed, and 3.2% outliers. The pH 7.0 structure was also solved by molecular
replacement using PHASER and the domain 1–5 structure previously solved. The
model was refined using PHENIX and iteratively rebuild in COOT and showed
reasonable stereochemistry, with 83.2% in the Ramachandran favored zones, 12.6%
in the allowed, and 4.2% outliers.
Expression and purification of PPT1. Recombinant human PPT1 protein was
expressed and purified following the protocol outlined in Lu et al. 201052.
Generation of model from PDB 68PI with M6P bound to domain 3. We used
SwissModel to generate a model of human domains 1–5 bound to M6P based on
Fig. 7 Domains 1–5 adopt a more compact conformation at pH 4.5 compared to pH 6.5. a A plot of the calculated Stokes radius derived from SEC data
collected under different pH conditions for domains 1–5, domains 7–15, and domains 1–15. b The observed changes in calculated Stokes radius (ΔRs) for
domains 1–5, 7–15, and 1–15 normalized per number of domains in each construct. c FPOP analysis of domains 1–5 at pH 6.5 versus 4.5 revealing peptides
protected (red shaded region) or exposed (green shaded region) (colored by domain: d1, blue; d2, magenta; d3, green; d4, orange; or d5, cyan) upon
lowering of pH to that of the endosome. d The overlay of Cα atoms of domain 1 of N-terminal 5 domains of full-length CI-MPR of the cryo-EM structure
determined at pH 4.5 (gray ribbon) (PDB 6UM1) with our domain 1–5 structure crystallized at pH 5.5 (PDB 6P8I) (domain 5 bound to the oligosaccharide
of a crystallographic neighbor). Strands 2 and 3 of both domain 4 structures have been labeled and circled with either a solid red line (PDB 6P8I) or a
dashed red line (6UM1) to illustrate displacement of domain 4. e Enlargement of the area in d showing the intersection of domains 2, 4, and 5.
Displacement of sulfur atoms (reported in Å) of disulfide bonds (red arrows) between structures PDB 6UM1 and PDB 6P8I illustrating the change in
orientation of domains at lower pH and in the absence of a bound CRD. f Mapping of FPOP data from c and Supplementary Fig. 6a onto domains 1–5 of pH
4.5 cryo-EM model (PDB 6UM1). Peptides showing a higher degree of protection at pH 4.5 versus 6.5 are mapped (red spheres) onto the SAXS-based
model of domains 1–5 in the absence of ligands, while those showing less protection are mapped as green spheres. Model regions undergoing no
statistically significant changes or lacking data are represented as ribbons. The lowering of the pH causes strand 2 of domain 4 to become less protected
while the atoms of strand 3 (circled in black) become more protected under these conditions.
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our two structures: PDB 1SYO and PDB 6P8I53. We next superimposed the Cα
atoms of domain 1 of the two structures and then appended the transposed
coordinates for domains 1–4 to the bound human domains 1–3 SwissModel
generated model yielding a new model of human domains 1–5 with ligand bound
to domains 1 and 5.
Purification of protein for other biophysical studies. Human domain 1–5
protein for SAXS, SPR, negative stain, EM, and SEC was generated as follows. Cells
were removed from the medium by centrifugation at 1000 g and the pH of the
medium was adjusted to pH 8.0 with 10-M NaOH. Precipitates were removed from
the medium by centrifugation at 4000 g before loading over 5 ml of PROTEINDEX
Ni-Penta agarose 6 fast flow resin (Marvelgent Biosciences). The resin was washed
with 20-mM Tris pH 7.6, 300-mM NaCl, and 20-mM imidazole before elution with
20-mM Tris pH 7.6, 300-mM NaCl, and 100-mM imidazole. Fractions were
analyzed by SDS-PAGE, pooled, and concentrated to 1 mg/ml before overnight
dialysis at 4 °C into 20-mM Tris, pH 7.6 at 22 °C, 150-mM NaCl. C-terminal tags
were removed by incubation overnight at 4 °C with Thrombin (Sigma). Thrombin
was removed by passage over benzamidine agarose beads. Domain 1–5 protein was
also incubated with PNGaseF overnight at 22 °C to remove N-linked glycans.
Proteins were passed over Ni-NTA agarose to remove cleaved His-tags as well as
PNGaseF (His-tagged). Flow-through and proteins eluted with 20-mM Tris pH 7.5
at 22 °C, 150-mM NaCl were combined and dialyzed overnight at 22 °C in column
buffer (50-mM imidazole, pH 6.5, 150-mM NaCl, 5 m β-glycerol phosphate,
10-mM MnCl2). Protein was further purified by passing dialyzed proteins over a
1-ml PPT1 amine coupled agarose resin column (10 mg/ml) (Pierce NHS-activated
agarose slurry). Loaded protein was washed with column buffer before elution with
20-mM MES, pH 4.5, 150-mM NaCl, 5 mM β-glycerol phosphate, 10-mM MnCl2
and neutralization with Tris buffer to pH 7.4. Any aggregates or contaminants were
removed by passage over a Superdex G200 10/300 column equilibrated in column
buffer without MnCl2. Monomeric fractions were pooled and stored at 4 °C.
Protein concentration was determined using the Bradford assay (Bio-Rad) with
bovine serum albumin as the standard.
Purification of other CI-MPR constructs. Domains 1–3, 7–15, and 1–15 protein
for SPR and/or SEC were expressed in Sf9 cells grown, harvested, and purified as
described in the previous section without treatment with thrombin and PNGaseF.
LC-MS/MS analysis of PPT1 glycosylation. Aliquots of PPT1 (20 μg) were
reduced, carboxyamidomethylated, dialyzed against nanopure water at 4 °C over-
night, and then dried in a Speed Vac. The dried, desalted sample was resuspended
and digested with trypsin (Promega, sequence grade) at 37 °C overnight. Following
digestion, the sample was again dried and subsequently resuspended in solvent A
(0.1% formic acid in water) and passed through a 0.2-µm filter (Nanosep, PALL)
before analysis by LC-MS/MS.
LC-MS/MS analysis was performed on an Orbitrap Fusion equipped with an
EASY nanospray source and Ultimate 3000 autosampler LC system (Thermo
Fisher). Resuspended tryptic peptides were chromatographed on a nano-C18
column (Acclaim pepMap RSLC, 75 μm× 150 mm, C18, 2 μm) with an 80-min
gradient of increasing mobile phase B (80% acetonitrile, 0.1% formic acid in
distilled H2O) at a flow rate of 300 nl/min routed directly into the mass
spectrometer. Full MS spectra were collected at 60,000 resolution in FT mode and
MS/MS spectra were obtained for each precursor ion by data-dependent scans
(top-speed scan, 3 s) utilizing CID, HCD, or ETD activation and subsequent
detection in FT mode.
Phosphorylated glycopeptides were annotated by manual data interpretation of
the LC-MS/MS data following initial processing by Byonic software (Protein
Metrics). Byonic parameters were set to allow 20 ppm of precursor ion
monoisotopic mass tolerance and 20 ppm of fragment ion tolerance. Byonic
searches were performed against the human PPT1 sequence allowing modification
with phosphorylated and non-phosphorylated human/mammalian N-glycans.
SPR studies of CI-MPR domains 1–5. All SPR measurements were performed at
25 °C using a Biacore 3000 instrument (BIAcore, GE Healthcare, Piscataway, NJ) as
previously described17,18. Purified lysosomal enzymes (GAA mono- and diester,
PPT1) were immobilized at a density of ~1000 RU on a CM5 sensor chip by
Fig. 8 Occlusion of carbohydrate-binding site of domain 9 of endogenous bovine CI-MPR in the presence of IGF2 (PDB 6UM2) supporting hypothesis
that CI-MPR ligand binding is allosterically regulated. a Cartoon representation showing domain 9’s (blue) C-terminal β sheet’s interaction with the N-
terminal β sheet of domain 8 (teal). The binding site of domain 9 faces into domain 6 (salmon) restraining loops B and C essential for ligand binding. The
four essential carbohydrate-binding residues (sticks: Gln, Arg, Glu, and Arg) of domain 9 are shown. Adjacent domains (domains 6, 8, and 11) are
represented as molecular surfaces. The second panel is rotated 90° downward along the x-axis relative to the first panel. b Cartoon representation
illustrating the change of position in domain 9 of CI-MPR (PDB 6UM1) when exposed to pH 4.5 buffer conditions compared to pH 7.4 in the presence of
IGF2 (a). For clarity, the second panel is rotated 180° along the y-axis relative to the original showing the change in solvent accessibility of the binding site
at pH 4.5.
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primary amine coupling following the manufacturer’s procedure. The reference
surface was treated the same way except for no protein addition. Purified domains
1–5 and domains 1–5 with PPT1 were prepared in 50-mM imidazole, 150-mM
NaCl, 5-mM MgCl2, 5-mM MnCl2, 5-mM CaCl2, pH 6.5 supplemented with
0.005% (v/v) P20. All samples were incubated for 2 h before loading on the
instrument. Samples were injected in a volume of 80 μl over the reference and
coupled flow cells at a flow rate of 40 μl/min for 2 min before dissociation with
buffer alone for 2 min. The sensor chip surfaces were regenerated with a 20-μl
injection of 10-mM HCl at a flow rate of 10 μl/min and allowed to re-equilibrate
with running buffer for 1 min before the next injection. The response at equili-
brium (Req) was determined for each concentration of protein/complex by aver-
aging the response over a 10-s period within the steady-state region of the
sensorgram (BIAevaluation software package, 4.0.1). Scatchard analysis was per-
formed to determine linear regions (10–40 nM) and (50–200 nM). The Req was
plotted for these two regions versus the concentration of protein and fit to a 1:1
binding isotherm. All responses were double-referenced by subtracting the change
in refractive index for the flow cell derivatized in the absence of protein from the
binding sensorgrams.
SAXS data collection on CI-MPR domains 1–5. SAXS was performed at BioCAT
(Sector 18) Advanced Photon Source utilizing a Pilatus 1M detector. Data was
collected at ~20 °C with a wavelength of 1.033 Å and ~3.5 m sample-to-detector
distance (q range= 0.00535–0.387 Å−1). Before introduction into the stationary
SAXS quartz capillary (1.5 mm ID, 1.52 mm OD), 0.5 mg of domains 1–5 protein
was incubated with 10-mM M6P in 50-mM imidazole, pH 6.5, 150-mM NaCl,
5-mM β-glycerol phosphate for 1 h at 22 °C. Batch mode SAXS data were collected
on human domains 1–5 alone, and in complex with M6P. SEC-SAXS was per-
formed on domains 1–5 in complex with PPT1, PPT1 alone and domains 1–5
protein alone. For the complex, 1.25 mg of domains 1–5 was incubated with 5 mg
of PPT1 in the above imidazole buffer for 1 h at 22 °C before data collection. SEC/
SAXS data were collected simultaneously (0.5-s exposures collected every 3 s) upon
elution from a
10/300 Superdex G200-Increase column equilibrated in matched buffer and at a
flow rate of 0.75 ml/min. Free domains 1–5 protein could not be completely
separated from that in complex with PPT1 as seen in the chromatogram. Exposures
flanking the elution peaks were averaged to generate the I(q) versus q curve for the
buffer and then subtracted from the elution peak curves to obtain the sample SAXS
curves. Data were processed with Primus54 and ab initio dummy atom modeling
was done with DAMMIF55. The merged SAXS curves were used to generate pair
distribution functions, P(r), and Kratky plots (PRIMUS). The flexibility analysis
curves were generated using SCATTER 3.0 software. The FoXS server was used to
compute the SAXS profile using the coordinates from the pH 5.5 structure (PDB
6P8I). The MultiFoXS server was used to calculate the population-weighted
ensemble fitting to the unbound protein scattering curves.
EM on CI-MPR domains 1–5. The negative-stained EM specimens of domains 1–5
and the domains 1–5 bound to M6P were prepared as described above. In brief, the
samples were diluted to ~0.001 μg mL−1 with sample buffer. An aliquot (~4 μL) of
diluted sample was placed on an ultra-thin carbon-coated 200-mesh copper grid
(CF200-Cu-UL, Electron Microscopy Sciences, Hatfield, PA, USA, and Cu-200CN,
Pacific Grid-Tech, San Francisco, CA, USA) that had been glow-discharged for 15
s. After 1-min incubation, the excess solution on the grid was blotted with filter
paper. The grid was then washed with water and stained with 1% (w/v) uranyl
formate before air-drying with nitrogen. The EM samples were examined by using
a Zeiss Libra 120 Plus TEM (Carl Zeiss NTS) operated at 120-kV high tension with
a 10–20 eV energy filter. The OpNS micrographs were acquired under defocus at
~0.6 μm and a dose of ~40–90 e−Å−2 using a Gatan UltraScan 4K × 4K CCD
under a magnification of 80 kx (each pixel of the micrographs corresponds to
1.48 Å in specimens). The contrast transfer function of each micrograph was
examined by using ctffind3 software56 and the phase and amplitude were corrected
by using the “TF CTS” command in SPIDER57 software or GCTF58 after the X-ray
speckles were removed. Particles were then selected from the micrographs by using
boxer (EMAN software59). All particles were masked by using a round mask
generated from SPIDER software after a Gaussian high-pass filtering. The 50
reference-free class averages of particles were obtained by using refine2d (EMAN
software) based on ~3000 particles windowed from ~140 micrographs.
Size-exclusion chromatography of truncated constructs. A G200-Increase
10/300 column was run at a flow rate of 0.75 ml/min and equilibrated with either
pH 6.5 buffer (20-mM imidazole, 150-mM NaCl, pH 7.5), pH 5.5 buffer (20-mM
sodium citrate, 150-mM NaCl, pH 5.5), pH 4.8 buffer (20-mM sodium citrate,
150-mM NaCl, pH 4.8), or pH 4.5 buffer (20-mM sodium citrate, 150-mM NaCl,
pH 4.5). Domains 1–5 protein was run at all the above-listed pH values while
domains 7–15 and 1–15 were run at pH 6.5 and 4.5. All proteins were injected onto
the column as 50 μg in 200 μl of matched pH buffer. Stokes radius was calculated
using thyroglobulin (bovine thyroid), β-amylase (sweet potato), albumin (bovine
albumin), carbonic anhydrase (erythrocytes), and cytochrome c (horse heart).
FPOP of human CI-MPR domains 1–5. A final concentration of 5-µM domains
1–5 protein was incubated in the 5-mM sodium citrate buffer in the presence or
absence of 5-µM PPT1 at pH 6.5 for 1 h. For FPOP at pH 4.5, 5-mM sodium citrate
buffer was used to incubate CI-MPR domain 1–5 for 1 h without PPT1. FPOP was
performed as described previously60. Briefly, 20 µl of protein sample mixture
containing 1-mM adenine, 17-mM glutamine, and 100-mM hydrogen peroxide
was irradiated by flow through the path of the pulsed ultraviolet laser beam from a
Compex Pro 102 KrF excimer laser (Coherent, Germany). The laser fluence was
calculated to be ~10.1 mJ/mm2/pulse. The laser repetition rate was 15 Hz. The flow
rate was adjusted to 13 μL/min to ensure a 15% exclusion volume between irra-
diated segments. After laser illumination, each replicate was collected in a
microcentrifuge tube containing 25 µl of quench mixture that contained 0.5-µg/µl
H-Met-NH2 and 0.5-µg/µl catalase to eliminate secondary oxidants. The adenine
hydroxyl radical dosimetry readings were measured at 265 nm in nanodrop
(Thermo Scientific) to ensure that all the samples were exposed to equivalent
amounts of hydroxyl radical61. All FPOP experiments were performed in triplicate
for statistical analysis.
After FPOP and quenching, 50-mM Tris, pH 8.0 containing 1-mM CaCl2,
5-mM DTT was added to the protein samples and incubated at 95 °C for 15 min to
denature and reduce the protein. The sample was cooled on ice, trypsin with 1:20
ratio of trypsin:protein was added and incubated at 37 °C for 12 h with rotation.
Sample digestion was stopped by adding 0.1% formic acid and the samples were
analyzed on a Dionex Ultimate 3000 nano-LC system coupled to an Orbitrap
Fusion Thermo Scientific (San Jose, CA). Samples were trapped on a 300-µM id X5
mm PepMap 100, 5-µm (Thermo Scientific) C18 trapping cartridge, then back-
eluted onto an Acclaim PepMap 100 C18 nanocolumn (0.75 × 150 mm, 2 μm,
Thermo Scientific). Separation of peptides on the chromatographic system was
performed using a binary gradient of solvent A (0.1% formic acid in water) and
solvent B (0.1% formic acid in acetonitrile) at a flow rate of 0.30 μL/min. The
peptides were eluted with a gradient consisting of 2–10% solvent B over 4 min,
increasing to 32% B over 25 min, ramped to 95% B over 4 min, held for 4 min, and
then returned to 2% B over 2 min and held for 8 min. Peptides were eluted directly
into the nanospray source of an Orbitrap Fusion instrument using a conductive
nanospray emitter obtained from Thermo Scientific. All the data were collected in
positive ion mode. Collision-induced dissociation CID was used to fragment
peptides, with an isolation width of 3 m/z units. The spray voltage was set to 2400
V, and the temperature of the heated capillary was set to 300 °C. Full MS scans
were acquired from m/z 350 to 2000 followed by eight subsequent MS2 CID scans
on the top eight most abundant peptide ions.
Peptides from tryptic digests of CI-MPR domain 1–5 were identified using
ByOnic version v2.10.5 (Protein Metrics). The search parameters included all
possible major oxidation modifications as variable modifications and the enzyme
specificity was set to cleave the protein after arginine and lysine residues. The peak
intensities of the unoxidized peptides and their corresponding oxidation products
observed in LC-MS were used to calculate the average oxidation events per peptide
in the sample as previously reported37. Briefly, peptide level oxidation was
calculated by adding the ion intensities of all the oxidized peptides multiplied by
the number of oxidation events required for the mass shift (e.g., one event for +16,
two events for +32) and then divided by the sum of the ion intensities of all
unoxidized and oxidized peptide masses as represented by Eq. (1)
P ¼ Iðþ16Þoxidized ´ 1þ Iðþ32Þoxidized ´ 2þ Iðþ48Þoxidized ´ 3þ ¼ =½
Iunoxidizedþ Iðþ16Þoxidized þ Iðþ32Þoxidizedþ Iðþ48Þoxidized:::½ ; ð1Þ
where P denotes the oxidation events at the peptide level and I values are the peak
intensities of oxidized and unoxidized peptides61.
Generation/energy minimization of a glycosylated PPT1 model. The 3D
structure of PPT1 (PDB code 3GRO) with M6GN2 (DManpα1–6[DManpα1–3]
DManpα1–6[DManpα1–2DManpα1–3]DManpα1–4DGlcpNAcβ1–4DGlcpNAcβ1-)
conjugated to (N197, N212, and N232) using the glycoprotein builder available at
GLYCAM-Web (www.glycam-web.org) and an in-house program that adjusts the
glycosidic linkages to relieve any atomic overlaps between the conjugated glycan
and the underlying protein. The glycosylated PPT1 structure was placed in a
periodic box of ~15,000 TIP5P waters with a 10 Å buffer between the glycoprotein
and the box edge. Energy minimization of all atoms was performed for 20,000 steps
(10,000 steepest descent, followed by 10,000 conjugant gradient).
MD simulations. All MD simulations were performed with the CUDA imple-
mentation of the PMEMD62 simulation code, as present in the Amber14 software
suite63. The GLYCAM06 force field64 and Amber14SB force field 65 were employed
for the carbohydrate and protein moieties, respectively. A Berendsen barostat with
a time constant of 1 ps was employed for pressure regulation, while a Langevin
thermostat with a collision frequency of 2 ps−1 was employed for temperature
regulation. A nonbonded interaction cutoff of 8 Å was employed. Long-range
electrostatics were treated with the particle-mesh Ewald method66. Covalent bonds
involving hydrogen were constrained with the SHAKE algorithm, allowing an
integration time step of 2 fs67 to be employed. All simulations were performed
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under nPT conditions and the restraints employed were 5-kcal/mol-Å2 Cartesian.
The energy minimized coordinates were equilibrated at 300 K over 400 ps with
restraints on the solute heavy atoms. The system was then equilibrated with
restraints on the Cα atoms of the protein for 1 ns, before performing a production
MD simulation for 500 ns, but with restraints applied only to the Cα atoms of
residues on either sides of gaps, namely (11, 12, 20, 21, 25, 26, 44, 45, 78, 79, 98, 99,
184, 185, 190, 191, 236 and 237. AMBER numbering).
Modeling of interaction between PPT1 and domains 1–5. The glycosylated
PPT1 structure was aligned to the Man6P in the d3 binding site of the “bound”
form of the d1–5 structure. The alignment was performed by superimposing the
nonreducing terminal mannose residue on the DManpα1–2DManpα1–3 arm of
M6GN2 at N197 onto the complexed Man6P. This process was repeated for
100 snapshots taken at regular intervals from the MD simulation trajectory. An in-
house program was employed to adjust the glycosidic linkages in N232 and N212
to bring N212 into contact with the region identified by the “hot spot” analysis. The
program adjusts the glycosidic linkages within known low-energy ranges68 while
avoiding atomic overlaps, as described previously69.
Fitting model of domains 1–5 bound to PPT1 to SAX data. The UCSF-Chimera
1.1270 program was employed to fit the co-complex of d1–5 with glycosylated
PPT1. Snapshots from the MD simulation of PPT1 were aligned to the “bound”
form of d1–5 via N232 as described in the previous “Modeling of multimeric
interaction” section. These structures were then fit into the SAX data using the map
fitting feature of UCSF Chimera with 50 fittings per structure and a 90% cutoff.
Statistics and reproducibility. Statistical analysis was performed using Prism
software for SPR experiments and EXCEL for FPOP.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
All data generated or analyzed during this study are included in the published article and
its Supplementary Information. The X-ray crystal structures and structure factors of
human domains 1–5 of CI-MPR at pH 5.5 and 7.0 have been deposited in Protein Data
Bank under accession codes PDB 6P8I and PDB 6V02. SAXS data have been deposited at
SASDBD with codes: SASDHL4 (N-terminal domains 1–5 of the cation-independent
mannose 6-phosphate receptor (CI-MPR)), SASDHM4 (N-terminal domains 1–5 of the
cation-independent mannose 6-phosphate receptor (CI-MPR) from SEC-SAXS),
SASDHN4 (N-terminal 5 domains of the cation-independent mannose-6-phosphate
receptor (CI-MPR) bound to mannose 6-phosphate (M6P)), SASDHP4 (palmitoyl-
protein thioesterase 1 (PPT1)), and SASDQ4 (N-terminal domains 1–5 of the cation-
independent mannose 6-phosphate receptor (CI-MPR) in complex with palmitoyl-
protein thioesterase 1 (PPT1)).
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